Dupilumab is a humanised IgG4 monoclonal antibody that exerts its anti-inflammatory properties by binding to the IL-4Rα receptor to mediate IL-13 and IL-4 activity.1 It has been shown in phase 3 randomised controlled trials (RCTs) to improve FEV1, severe exacerbation frequency and symptom control in persistent asthma.2 There is a paucity of data looking at the impact of dupilumab therapy on small airways dysfunction (SAD) despite the latter being closely associated with type 2 inflammation and asthma control.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: